Jack Cohen, MD
Retina Specialist · Harvey, ILNPI 1205836947
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (56.0%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 96.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $13,502 and has fallen 99.0% since, to $131 in 2025.
Across 30 payments — averaging $791.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$23K
- Regeneron Healthcare Solutions, Inc.$285
- Sandoz$169
- Novartis$146
- Genentech USA, Inc.$73
- Apellis Pharmaceuticals, Inc.$70
- plus $151 from 4 others
What the payments were for
- Food & beverage$8514%
- Education$430%
- Ownership interest$9,54540%
- Other$13,30456%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 7 | $22,849 |
| Regeneron Healthcare Solutions, Inc. | 9 | $285 |
| Sandoz | 1 | $169 |
| Novartis | 2 | $146 |
| Genentech USA, Inc. | 3 | $73 |
| Apellis Pharmaceuticals, Inc. | 3 | $70 |
| ANI Pharmaceuticals, Inc. | 2 | $53 |
| AstraZeneca | 1 | $43 |
| Lumibird Medical Inc. | 1 | $34 |
| Coherus Oncology, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,743 in reported general payments places this provider in the 80th percentile of 70 retina specialist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 224 | $9,550 |
| Bromfenac Sodium | 35 | $7,204 |
| ProlensaBromfenac Sodium | 14 | $5,432 |
| Ketorolac Tromethamine | 211 | $4,458 |
| Difluprednate | 19 | $2,320 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 38 | $557 |
| Atropine Sulfate | 12 | $512 |
| Dorzolamide Hcl | 39 | $493 |
| Latanoprost | 26 | $263 |
| Timolol Maleate | 20 | $262 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Harvey
- Mathew MaccumberHarvey$219K
- Kourous RezaeiHarvey$126K
- Kirk PackoHarvey$86K
- David OrthHarvey$70K
- Timothy FloodHarvey$57K
- Serge DebustrosHarvey$34K
- Vivek ChaturvediHarvey$34K
- Sohail HasanHarvey$30K
- Zac RavageHarvey$12K
- Naryan SabherwalHarvey$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.